Skip to main content
NCBI home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
letter
. 2010 Apr 19;85(7):535–537. doi: 10.1002/ajh.21738

A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B‐precursor acute lymphoblastic leukemia cell lines†

Takeshi Inukai 1,✉, Xiuru Zhang 2, Takeshi Kameyama 2, Yukiko Suzuki 2, Kazuhito Yoshikawa 2, Itaru Kuroda 1, Atsushi Nemoto 1, Koshi Akahane 1, Hiroki Sato 1, Kumiko Goi 1, Kazunori Nakamoto 3, Jun‐ichi Hamada 2, Mitsuhiro Tada 2, Tetsuya Moriuchi 2, Kanji Sugita 1
PMCID: PMC7159455  PMID: 20575032

The content is available as a PDF (828.6 KB).

†

Conflict of interest: Nothing to report

References

  • 1. Hong H,Takahashi K,Ichisaka T, et al. Suppression of induced pluripotent stem cell generation by the p53‐p21 pathway. Nature 2009; 460: 1132–1135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Fenaux P,Jonveaux P,Quiquandon I, et al. Mutations of the p53 gene in B‐cell lymphoblastic acute leukemia: A report on 60 cases. Leukemia 1992; 6: 42–46. [PubMed] [Google Scholar]
  • 3. Wada M,Bartram CR,Nakamura H, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993; 82: 3163–3169. [PubMed] [Google Scholar]
  • 4. Marks DI,Kurz BW,Link MP, et al. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996; 87: 1155–1161. [PubMed] [Google Scholar]
  • 5. Lanza C,Gaidano G,Cimino G, et al. Distribution of TP53 mutations among acute leukemias with MLL rearrangements. Genes Chromosomes Cancer 1996; 15: 48–53. [DOI] [PubMed] [Google Scholar]
  • 6. Kawamura M,Kikuchi A,Kobayashi S, et al. Mutations of the p53 and ras genes in childhood t(1;19)‐acute lymphoblastic leukemia. Blood 1995; 85: 2546–2552. [PubMed] [Google Scholar]
  • 7. Nakai H,Misawa S,Tanaka S, et al. p53 Gene mutations and loss of a chromosome 17p in Philadelphia chromosome (Ph1)‐positive acute leukemia. Leukemia 1993; 7: 1547–1551. [PubMed] [Google Scholar]
  • 8. Drexler HG,Fombonne S,Matsuo Y, et al. p53 Alterations in human leukemia‐lymphoma cell lines: In vitroartifact or prerequisite for cell immortalization? Leukemia 2000; 14: 198–206. [DOI] [PubMed] [Google Scholar]
  • 9. Inukai T,Zhang X,Goto M, et al. Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor‐related apoptosis‐inducing ligand: A possible mechanism for poor sensitivity to antitumor immunity. Leukemia 2006; 20: 2119–2129. [DOI] [PubMed] [Google Scholar]
  • 10. Uno K,Inukai T,Kayagaki N, et al. TNF‐related apoptosis‐inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome‐positive leukemia cells. Blood 2003; 101: 3658–3667. [DOI] [PubMed] [Google Scholar]
  • 11. Akahane K,Inukai T,Inaba T, et al. Specific induction of CD33 expression by E2A‐HLF: The first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor. Leukemia 2010; 24: 865–869. [DOI] [PubMed] [Google Scholar]
  • 12. Flaman JM,Frebourg T,Moreau V, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92: 3963–3967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Nakamura M,Sugita K,Inukai T, et al. p16/MTS1/INK4A Gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. Leukemia 1999; 13: 884–890. [DOI] [PubMed] [Google Scholar]
  • 14. Ohyashiki K,Fujieda H,Miyauchi J, et al. Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t(17;19) chromosomal translocation the growth of which is inhibited by interleukin‐3. Leukemia 1991; 5: 322–331. [PubMed] [Google Scholar]
  • 15. Takahashi H,Goto H,Eunabiki T, et al. Expression of two types of E2A‐HLF fusion proteins in YCUB‐2, a novel cell line established from B‐lineage leukemia with t(17;19). Leukemia 2001; 15: 995–997. [DOI] [PubMed] [Google Scholar]
  • 16. Uphoff CC,MacLeod RA,Denkmann SA, et al. Occurrence of TEL‐AML1 fusion resulting from (12;21) translocation in human early B‐lineage leukemia cell lines. Leukemia 1997; 11: 441–447. [DOI] [PubMed] [Google Scholar]
  • 17. Nakamura M,Sugita K,Inukai T, et al. Abnormalities of the p16INK4a gene in childhood B‐precursor acute lymphoblastic leukemia without nonrandom translocations: Analysis of seven matched pairs of primary leukemia and corresponding cell line. Leukemia 2001; 15: 1136–1139. [DOI] [PubMed] [Google Scholar]
  • 18. Cheng J,Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T‐cell lines. Mol Cell Biol 1990; 10: 5502–5509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Diccianni MB,Yu J,Hsiao M, et al. Clinical significance of p53 mutations in relapsed T‐cell acute lymphoblastic leukemia. Blood 1994; 84: 3105–3112. [PubMed] [Google Scholar]
  • 20. Altura RA,Inukai T,Ashmun RA, et al. The chimeric E2A‐HLF transcription factor abrogates p53‐induced apoptosis in myeloid leukemia cells. Blood 1998; 92: 1397–1405. [PubMed] [Google Scholar]
  • 21. Bedi A,Barber JP,Bedi GC, et al. BCR‐ABL‐mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148–1158. [PubMed] [Google Scholar]
  • 22. Kashiwazaki H,Tonoki H,Tada M, et al. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene 1997; 15: 2667–2674. [DOI] [PubMed] [Google Scholar]
  • 23. Takahashi M,Tonoki H,Tada M, et al. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 2000; 89: 92–99. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Hematology are provided here courtesy of Wiley

RESOURCES